Request Discount

COVID-19 Vaccines Market (Type - mRNA-based Vaccine, Adenovirus Vaccine, Recombinant Adenovirus Vaccine, Non-replicating Viral Vector, and Inactivated Vaccine): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026

  • Published : April, 2021

  • Rep Id : HC0067

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on covid-19 vaccines market provides in-depth analysis of segments and sub-segments in the global as well as regional covid-19 vaccines market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional covid-19 vaccines market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global covid-19 vaccines market. According to the report, the global covid-19 vaccines market is projected to grow with a healthy CAGR over the forecast period of 2020-2026.


Market Insight

COVID-19 vaccines are the most important tools to slow and reduce the spread and impact of the COVID-19 pandemic. Several biopharmaceutical companies have made exceptional progress in advancing treatments and vaccines to help fight COVID-19. More than a dozen vaccines have achieved regulatory authorization around the globe and many more remain in phase 1-3 clinical trials and in the early stages of development. BNT162b2, developed by Pfizer and BioNTech, and Moderna’s COVID-19 Vaccine are among the first authorized vaccines indicated for the virus. Moreover, Johnson & Johnson’s adenovirus vector-based Janssen COVID-19 Vaccine Candidate, Novavax’s nanoparticle vaccine NVX-CoV2373, GlaxoSmithKline (GSK) and Vir Biotechnology’s antiviral antibody VIR-7831, CureVac’s mRNA-based vaccine CVnCoV, Merck & Co.’s oral antiviral agent molnupiravir, also called MK-4482 and Sanofi and GlaxoSmithKline (GSK)’s recombinant protein-based vaccine incorporating a Sanofi antigen and GSK adjuvant are also in development stages. Particularly, mRNA-based vaccines have gained huge recognition after the quick development of two candidates to protect the immune system against SARS-CoV-2.


COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 was one of the largest disruptors of the global economy. With more than 131 million cases of COVID-19 and 2.85 million deaths globally, this pandemic has swept through countries around the world within a year and is the worst in more than 100 years. Therefore, with high rate of transmission, the market for the COVID-19 vaccine looks very promising for the upcoming years. Currently, as the entire health care system is primarily focused on treating and developing vaccines for this virus, the major vaccine manufacturers across the globe will experience significant growth during the forecast period. Another notable development is the growth of the Indian market with a large number of biopharma companies are also collaborating with multinational biopharma firms. Recently, vaccine and pharma major Panacea Biotec has collaborated with a growing list of Indian firms to produce Sputnik V, the Russian vaccine against COVID-19. The company is also partnering with India's Bharat Biotech, a developer of the vaccine, to commercialize the shot in the United States. Further, the rising government funding will also accelerate the rollout of vaccines for COVID-19. For instance, the U.S. government has allocated over USD 9 billion to develop and manufacture candidate vaccines. In addition, initiatives by global collaborations such as COVAX, the vaccines pillar of the Access to Covid-19 Tools Accelerator (ACT-Accelerator) are also anticipated to accelerate the development, production, and equitable access to new Covid-19 vaccines. Apart from that, regulatory approval of COVID-19 vaccines is also being fast-tracked globally which will further accelerate the growth of the market.


Geographically, North America holds a significant share in the global COVID-19 vaccine market. The U.S. is one of the world’s most affected countries by coronavirus currently, which has increased the demand for the COVID-19 vaccines in the North American region. Furthermore, the presence of a large number of biotech players engaged in the development of COVID-19 vaccines also contributes to the growth of the North America COVID-19 vaccine market. Moderna and drug company partners Pfizer and BioNTech also have a huge market share in the U.S. and Canada markets. However, Europe will hold the second-largest share as seven European countries are among the ten most affected countries with coronavirus. Furthermore, most of the European countries have a large number of aging populations, due to which the demand for COVID-19 vaccines is high in Europe. According to a list compiled by the Center for Global Health at the University Institute for International Studies and Development, Germany is one of the world’s top investors in COVID-19 vaccine research along with the United States. 


Moreover, the Asia Pacific region is expected to grow at an unprecedented rate due to the high population in the region and the rising number of countries affected by COVID-19. Asian countries such as India, Japan, South Korea, Singapore, and Malaysia have a high rate of the spread of the virus, which will increase the demand for COVID-19 vaccines in the region. The biopharma market in South Africa is also expected to see a boost over the forecast period. BioVac Institute, a South African vaccine company also plans to utilize a contract the company won to manufacture coronavirus shots as a steppingstone toward developing an inoculation export industry in the country. The contract with U.S.-based ImmunityBio Inc., which is conducting phase 1 vaccine trials in South Africa and the U.S., will allow BioVac to transform itself from a facility that merely packages and labels the shots to one that makes the raw materials.


COVID-19 Vaccines Market

Segment Covered

The report on global covid-19 vaccines market covers segments such as type. On the basis of type, the sub-markets include mRNA-based vaccine, adenovirus vaccine, recombinant adenovirus vaccine, non-replicating viral vector, and inactivated vaccine.


Companies Profiled:

The report provides profiles of the companies in the market such as AstraZeneca plc, GlaxoSmithKline plc, Pfizer Inc., Bharat Biotech International Limited, Johnson & Johnson, Serum Institute of India, Novavax, iNC., Sinovac Biotech, CureVac N.V., and Moderna Inc.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of covid-19 vaccines market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount